Treatments: Papillary Thyroid Carcinoma
How papillary thyroid carcinoma is treated, from active surveillance and surgery through radioactive iodine, thyroid hormone therapy, and long-term follow-up.
Treatment overview
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, making up roughly 85% of cases. It arises from the hormone-producing cells of the thyroid, a butterfly-shaped gland at the front of the neck. It usually grows slowly and has an excellent outlook, especially when found early, and many people are cured. For background on what papillary thyroid carcinoma is and how it is diagnosed, see Conditions: Papillary Thyroid Carcinoma and Thyroid Cancer.
Because most papillary thyroid cancers behave gently, modern care is "risk-adapted." This means treatment is matched to how the individual cancer is expected to behave, including its size, whether it has spread to lymph nodes or beyond the thyroid, and its appearance under the microscope, rather than treating every cancer the same way. The main goal is to control the cancer while avoiding unnecessary side effects. Not every option described below applies to every person, and treatment decisions are typically made through shared decision-making between a patient and a care team, based on the specific features of the cancer and on the person's health and preferences. An overview of all thyroid cancer treatment approaches is available at Treatments for Thyroid Cancer (and Suspicious Nodules).
Active surveillance (close monitoring without immediate surgery)
For very small, low-risk cancers, generally 1 cm or smaller, confined to the thyroid, and without signs of spread to lymph nodes or nearby structures, one option is to watch the cancer closely rather than operate right away. This is called active surveillance.
Monitoring is typically done with a neck ultrasound about every 6 months for the first 1 to 2 years, and then once a year if the cancer stays stable.
Studies of thousands of people managed this way have shown excellent survival, with only a small percentage showing growth or spread over time.
If the cancer grows (for example, by about 3 mm or more), spreads to lymph nodes, or if a person prefers surgery at any point, an operation can be done then. Delaying surgery in carefully selected patients has not been shown to worsen outcomes.
Active surveillance is generally not appropriate for cancers with aggressive features, signs of invasion into nearby structures (such as the nerve to the voice box, the windpipe, or the swallowing tube), or spread to lymph nodes or other organs. It also depends on a commitment to regular follow-up.
Surgery
Surgery is the most common treatment for papillary thyroid carcinoma larger than about 1 cm. There are two main operations, described further on the Thyroidectomy page.
Lobectomy (removing half of the thyroid). This removes the lobe containing the cancer along with the isthmus, the strip of thyroid tissue in the middle. For low-risk cancers on one side, confined to the thyroid, and 4 cm or smaller, particularly those under 2 cm, lobectomy is often the approach used. It has a lower risk of complications and, for many people, leaves enough working thyroid tissue that a daily thyroid hormone pill is not needed. About 70 to 80% of people who have a lobectomy can avoid thyroid hormone supplements if the goal is a normal thyroid level.
Total thyroidectomy (removing the entire thyroid). This is generally used for cancers larger than 4 cm, cancers that have grown outside the thyroid, cancers that have spread to lymph nodes in the neck or to distant sites, and cancers with aggressive features under the microscope. It may also be used when cancer is present on both sides of the gland or when radioactive iodine treatment is planned, since that treatment depends on removal of the whole gland. Everyone who has a total thyroidectomy needs to take thyroid hormone for life.
Choosing between the two. For cancers between 1 and 4 cm on one side, either operation may be reasonable. Total thyroidectomy carries somewhat higher risks, including temporary or permanent low calcium levels (see Hypoparathyroidism) and injury to the nerve that controls the voice (see Laryngeal Nerve Dysfunction). Lobectomy has fewer complications but a slightly higher chance that a second operation (a "completion thyroidectomy") may be needed later if higher-risk features are found. These trade-offs are discussed further at Extent of Thyroid Surgery and Considerations in Extent of Thyroidectomy, and typical recovery after thyroidectomy is described separately.
Lymph node surgery. When lymph nodes in the neck are known to contain cancer, they are removed at the time of surgery (called a neck dissection; see Lymph Nodes). Removing normal-appearing lymph nodes "just in case" is generally not done for most papillary thyroid cancers, because it adds risk without clear benefit.
Radioactive iodine therapy
Radioactive iodine (RAI, iodine-131) is taken by mouth and is absorbed by thyroid cells, including any thyroid cancer cells left after surgery. It is used only after a total thyroidectomy and only for selected people. Its purposes are to destroy any remaining normal thyroid tissue (which makes follow-up blood tests more reliable), to treat possible microscopic cancer that could cause a recurrence, and to treat known cancer that has spread. More detail is available on the Radioiodine Ablation page.
Radioactive iodine is not used for everyone. Its use is guided by the risk that the cancer will come back:
It is not routinely needed for small, low-risk cancers confined to the thyroid, because it does not lower the recurrence rate in these cases.
It is considered selectively for intermediate-risk cancers, based on features such as tumor size, spread to lymph nodes, and blood test results.
It is generally used for higher-risk cancers, such as those growing beyond the thyroid, with extensive lymph node involvement, or with spread to distant organs, where it can improve outcomes.
Preparation usually involves either temporarily stopping thyroid hormone or receiving injections to raise thyroid-stimulating hormone (TSH), along with a low-iodine diet for a period beforehand. Possible side effects include dry mouth, altered taste, and salivary gland irritation, and, with high cumulative doses over time, rare longer-term risks. Radioactive iodine is avoided during pregnancy and breastfeeding. Some papillary thyroid cancers do not take up iodine well and are called "radioactive iodine-refractory"; these are managed with other approaches, described below.
Thyroid hormone and TSH-lowering therapy
After surgery, thyroid hormone (levothyroxine) is often prescribed. It serves two purposes: replacing the hormone the thyroid can no longer make (see Treatments for Hypothyroidism) and, in some cases, keeping the level of TSH low. TSH can encourage thyroid cancer cells to grow, so lowering it may reduce the chance of recurrence in higher-risk situations.
For people at higher risk or with known remaining cancer, TSH is usually kept below the normal range.
For people who are at low risk and free of disease, TSH is generally kept in the normal range, because strongly lowering it has little benefit and can cause side effects.
The degree of TSH lowering is re-evaluated over time and is often eased once a person has remained free of cancer.
Keeping TSH very low over the long term (which is controlled hyperthyroidism) can cause side effects such as an irregular heartbeat (especially in older adults) and thinning of the bones (especially in women after menopause). For this reason, targets are individualized to balance benefit against these risks, and adequate calcium and vitamin D intake is important for those taking TSH-lowering doses.
Treatment of advanced, recurrent, or spread disease
Most papillary thyroid cancer never reaches this stage, but when cancer comes back or spreads, several options exist:
More surgery is often the preferred approach when a recurrence in the neck can be removed.
Additional radioactive iodine may be used if the cancer still takes up iodine.
External beam radiation therapy can treat disease that threatens important structures in the neck.
Local treatments such as thermal ablation (using heat) or ethanol injection may be options for small, limited areas of disease in selected people.
Targeted drugs and other medicines are used for cancer that is progressing, causing symptoms, and no longer responds to radioactive iodine. These include medicines such as lenvatinib and sorafenib, and drugs aimed at specific genetic changes in the cancer (for example, BRAF, RET, or NTRK alterations). Testing the tumor for these changes can help match a person to a medicine. See Chemotherapy and Immunotherapy for general information.
Follow-up and monitoring
After treatment, follow-up typically includes physical exams, blood tests (including TSH and, when appropriate, a thyroid protein called thyroglobulin), and neck ultrasound. The frequency depends on the risk level. For low-risk cancers, monitoring may eventually stop after many years without recurrence. More is available at Monitoring for Thyroid Cancer Recurrence.
Key points
Papillary thyroid carcinoma usually grows slowly and has a very good prognosis.
Treatment is tailored to the individual cancer and can range from close monitoring to surgery, radioactive iodine, and medication.
Less aggressive treatment is now standard for many low-risk cancers, aiming to avoid unnecessary side effects while keeping outcomes excellent.
Treatment decisions are typically made together with a thyroid cancer care team, taking personal preferences into account.